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Tile hepatic IL-6-recaptor is composed of an 80 kDa IL-6-binding protein and a 130 kDa polypeptide (gp130) believod to be involved in signal 
transduction. Previous experiments have shown that the 80 kDa IL-6.receptor is up-regulated by glucocortieoids, but not by IL-6. Here we 
demonstrate that IL-6 together with the synthetic 81ucocorticold dexamethasone i duces the expression ofmRNA for gpl3O approximately S-fold 
in HepG2 cells. The induction was dose- and time-delYendent. Dexamethasone alone, interferon-7, IL-lrr and IL-Ip had no effect. A possible role 
for the regulation of the IL-6-signal transducing protein gpl30 in various inflammatory states is proposed. 
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1. INTRODUCTION 
IL-6 is a multifunctional eytokine involved in the 
immune response, in hematopoiesis and in the acute- 
phase reaction [1-5]. The main activities exerted by IL-6 
are induction of cell differentiation or gene activation 
and induction or inhibition of cell growth [1-5]. IL-6 
acts via cell-surface receptors on target cells. The IL-6- 
receptor (IL-6-R) is composed of an 80 kDa binding 
protein (gpg0) and a 130 kDa glycoprotein involved in 
signal transduction (gpl30). Both IL-6-R subunits have 
recently been identified by molecular cloning from 
human [6--8] and rodent sources [9,10]. The two IL-6-R 
subunits belong to a recently defined receptor super- 
family designated as the hematopoietic receptor family 
[11,12]. The members of the family are characterized by 
four conserved eysteine residues and a tryptophan- 
serine-x-tryptophan-serine (WSXWS) motif [13]. IL-6 is 
a major regulator of acute-phase protein synthesis in 
liver cells [14--17]. Therefore, the regulation of the he- 
patic 80 kDa-IL-6-R subunit has been studied. It was 
found that glucocorticoids, but not IL-6 up-regulated 
mRNA as well as functional protein expression of gp80 
[18,19]. Thus far, nothing is known about the regulation 
of the second subunit of the hepatic IL-6-R (gp130). 
In this study we show for the first time that the gpl30- 
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mRNA is slightly up-regulated by IL-6 and to a greater 
extent by the combination of IL-6 with dexamethason¢. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
Restriction enzymes and tile random primed DNA labeling kit were 
purchased from Boeltringer Mannhcim (Mannheim, Germany). [¢z- 
s:P]dCTP (! 10 TBq/mmol) was obtained from Amersham Interna- 
tional (Amersham, UK). DMEM wa~ from Gibco (Eggenstein, 
Germany). Recombinant human (rh)lL-6 was prepared as describcxl 
[20]. The specific activity obtained was in the range of 1.5 x 10 ~ B-cell 
stimulatory factor-2 units/rag protein [21]. RhlL-1ot and rhlL-Ifl with 
a specific activity of 2 × 10 ~ LAF unit~/mg protein was a geaerous gift 
of Dr. A.R. Shaw (Glaxo Institute for Molecular Biology, Geneva, 
Switzerland). RhlFN;, was obtained from Dr. E. Bill (Bioferon, 
Laupheim, Germany). 
2.2. Cell culture 
HepO2 cells were obtained from the American type culture collec- 
tion (Roekville, MD, USA) and cultured in DMEM/DMEM-FI2 
medium. Culture medium was supplemented with 10% fetal calf 
serum, streptomycin (100 rag/l) and penicillin (61 rag/l). Cells were 
grown at 37°C in a water.saturated atmosphere inthe presence of 5% 
CO,, 
2.3. RNA-preparatlon and Northern.blot analysis 
Total RNA was prepared using the phenol extraction method as 
described in [22,23]. 5/zg of RNA were heated to 65"C for 10 rain in 
50% formamide, 20 mM morpholinopropane sulphonie acid (MOPS), 
5 mM sodium acetate, i mM EDTA, 2.2 M formaldehyde prior to gel 
¢leetrophoresis in 1% agarose containing 2.2 M formaldehyde, 20mM 
MOPS, 5 mM sodium acetate and i mM EDTA. Equal oading of the 
RNA gel was checked by ethidium bromide staining of 18 S and 28 
S ribosomal RNA. The separated RNA was transfern.'d to Gene 
Screen Plus membranes (Dupont-NEN, Dreieich, Germany) ac- 
cording to supplier's instructions. 'fhe filters were prehybridized at 
68°C for 1 h in 10% dextrin sulfate, 1 M sodium chloride, 1% SDS 
and hybridized in the same solution with a 3 kb AeclIIBamHI gp 130 
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cDNA fragment labeled by random priming [24]. After hybridization 
unspeciflcally bound radioactivity was removed by washing in 2 x 
standard saline solution (SSC) at room temperature, t'ollowed by two 
consequent washes in 2 x SSC/I% SDS at 68*C for 30 rain each. The 
filters were then subjected to autoradiography using intensifying 
serg ,~Ds .  
3. RESULTS 
Fig. 1 shows the effect of  IL-6, dexamethasone, inter- 
feron-?-, IL- I~ and IL-Ip on the expression of gp130- 
mRNA in HepG2 cells by Northern analysis. It is evi- 
dent that dexamethason¢, interferon-?', I L - la  and IL- 
1/~ do not affect gpl30 gene expression. In contrast, 
IL-6 and in particular 1L-6 in combination with dexa- 
methasone led to a marked stimulation of b-'pI30- 
mRNA synthesis. The dose-dependent stimulation of  
gpl30-mRNA by IL-6 at a constant concentration of 
10 -6 M dexamethasone can be seen in Fig. 2. A steady 
increase in gp l30-mgNA levels was observed at IL-6 
concentrations > 10 units/ml. The stimulation ofgp130- 
mRNA synthesis by IL-6 is time-dependent (Fig. 3). A 
maximum of induction was found between 8 and 18 h. 
An overall gpl30-mRNA induction of about 5-fold was 
estimated. 
4. DISCUSSION 
Previous experiments from several aboratories have 
shown that acute-phase proteins are induced by IL-6 
and dexamethasone in vitro and in r ive [14-17,25]. In 
various inflammatory states elevated glucocorticoid lev- 
els are observed. We and others have described that 
gpg0-mgNA as well as the functional protein is induced 
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Fig. 1. Gpl30 mRNA expression in HepG2 cells treated with various 
q, tokiaes and dexamethasone. HepO2 cells were treated for 18 h with 
100 U/ml rhlL-6, 10 -~ M dexamethasone, 100U/ml IL-I=, 100 U/ml 
IL-I/~, or 100 U/mi IFN~,. Total RNA was isolated as deserib~ in 
section 2and subjected toNorthern-blot analysis. RNAs were probed 
with a gpl30.cDNA labelled by random priming. 
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Fig. 2. Dose dependence of gp 130 mRNA expression in HepG2 cells 
treated with IL-6 and dexamothasone. H pG2 cells were treated for 
18 h with 10 -~ M dexamethasone and various amounts of IL-6 as 
indicated in the figure. Northern-blot analysis was carried out as 
described in the legend to Fig. 1. 
by glucocorticoids and not by IL-6 [18,19]. In the pres- 
ent study, evidence is presented that IL-6 and in parti. 
cular the combination of  IL-6 and dexamethasonc 
stimulates gp130.mRNA expression in HepG2 cells. 
This clearly indicates that the expression of  the two 
IL-6-R subunits are regulated by different mechanisms. 
It has been published by Hibi et al. [8] that in HepG2 
cells gp130-mRNA levels are at least 5 times higher than 
those of  gpg0, Recent experimentsfrom our laboratory 
have shown that the exposure of  HepG2 cells to high 
doses of IL-6 leads to a rapid down-regulation of  IL-6 
binding sites (Zohlnh6fer et al., submitted). Having 
down-regulated their receptors, HepG2 cells became 
non-responsive to IL-6 in regard to acute-phase protein 
induction. However, responsiveness could be recon- 
stituted with the soluble form of  the 80 kDa-binding 
protcin/IL-6 complex (Mackiewicz et al., submitted), 
i.e. the soluble IL-6-R/IL-6 complex acts as an agonist 
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Fig. 3. Time de~ndenc¢ of gpl30 mRNA expression i  HepG2 cells 
treat~ with IL-6 and dexamethasone, l-I pG2 cells were treated with 
100 U/m1 IL-6 and 10 -~ M dexamethasone for the times indicated in 
the figure. Northern-blot analysis was done as described inthe legend 
to Fig. 1. 
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on liver cells depleted o f  membrane-bound gp80 by 
triggering the aggregat ion of  the soluble gp80 with 
gp l30  leading to  signal transduction [26]. The am- 
plitude o f  the IL -6 response seemed to be determined by 
the ratio o f  the two subunits o f  the IL -6-R on the cell 
surface; if the amount  o f  gpg0 is low, the cell loses 
responsiveness after an exposure to low levels o f  1L-6. 
However ,  such a refractory state could be overcome by 
the presence o f  the shlL-6-R. Finally, the amount  o f  
gp130 determines how many complexes o f  1L-6 bound 
to the membrane  or soluble form of  gpg0 can induce 
transduct ion of  a specific signal. Accordingly, it will be 
o f  importance to analyze in detail the amounts  and ratio 
o f  the two IL -6-R subunits in soluble form or  on the 
surface o f  IL-6 responsive cells. Interestingly, we found 
high levels o f  soluble IL-6-R in patient sera with chronic 
inf lammatory diseases like systemic lupus erythe- 
matodes and rheumatoid arthritis (H. Schoolt ink,  un- 
published results). 
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